摘要
目的探讨重组人血小板生成素(rh-TPO)与白细胞介素-11(IL-11)治疗急性白血病化疗后血小板减少症的临床效果和安全性比较。方法选取我院88例2017年1月至2018年7月收治的急性白血病化疗后血小板减少症患者为研究对象,采用随机数字表分组。IL-11治疗组采取皮下注射IL-11治疗,rh-TPO治疗组则采取皮下注射rh-TPO治疗。比较IL-11治疗组、rh-TPO治疗组的治疗效果;血小板计数达到75×10^9/L的时间、血小板计数达到125×10^9/L的时间;治疗前后患者血小板水平;心房颤动、心力衰竭、头痛、水肿等的发生率。结果与IL-11治疗组比较,rh-TPO治疗组有更高的疗效,P <0.05。rh-TPO治疗组血小板计数达到75×10^9/L的时间、血小板计数达到125×10^9/L的时间比IL-11治疗组更早,血小板计数变化幅度更大,P <0.05。rh-TPO治疗组心房颤动、心力衰竭、头痛、水肿等的发生率明显低于IL-11治疗组,P <0.05。结论皮下注射rh-TPO治疗急性白血病化疗后血小板减少症的效果理想,是值得推广的治疗方案。
Objective To investigate the clinical eff ect and safety comparison of recombinant human thrombopoietin(rh-TPO)and interleukin-11(IL-11)in the treatment of acute leukemia with thrombocytopenia after chemotherapy.Methods Eighty-eight patients with acute leukemia undergoing chemotherapy and thrombocytopenia in our hospital from January 2017 to July 2018 were selected as the research subjects,and they were grouped by a random number table.The IL-11 treatment group was treated with subcutaneous injection of IL-11,and the rh-TPO treatment group was treated with subcutaneous injection of rh-TPO.Compare the therapeutic eff ects of IL-11 treatment group and rh-TPO treatment group;the time for platelet count to reach 75×10^9/L and the time for platelet count to reach 125×10^9/L;platelet level of patients before and after treatment;atrial fi brillation,heart failure,The incidence of headache,edema,etc.Results Compared with IL-11 treatment group,rh-TPO treatment group had higher curative eff ect,P<0.05.The time for the platelet count to reach 75×10^9/L,the time for the platelet count to reach 125×10^9/L in the rh-TPO treatment group were earlier than those in the IL-11 treatment group,the change of platelet count was greater P<0.05.The incidence of atrial fi brillation,heart failure,headache,and edema in the rh-TPO treatment group was signifi cantly lower than that in the IL-11 treatment group,P<0.05.Conclusion Subcutaneous injection of rh-TPO is eff ective in treating acute leukemia thrombocytopenia after chemotherapy,and it is a treatment program worth promoting.
作者
王敏
WANG Min(Department of Hematology,Benxi Iron and Steel(Group)General Hospital,Benxi 117000,China)
出处
《中国医药指南》
2020年第26期73-74,共2页
Guide of China Medicine
